Redeye updates its view on Xbrane following a stronger-than-expected Q1 report, with both revenue and EBIT exceeding estimates. In the wake of the Alvotech deal, we see a new investment case emerging—still overshadowed by the turbulence of the past year, the current market cap remains modest for a commercial-stage biotech company.
LÄS MER
